Order by phone 1-866-808-5635 (M-F 9am-5pm CST) Help/FAQs / LawRewards / Gift Certificates

Your Discount Online Law Bookstore!

My Cart 0 $0.00
Only $48.99 until FREE SHIPPING!
Only $48.99 until FREE SHIPPING!
  • Menu
  • Account

Order by phone 1-866-808-5635 (M-F 9am-5pm CST)

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising (Instant Digital Access Code Only)

  • Edition : 1st, 2018
  • Author(s) : Stephany De Scisciolo; Teresa L. Scheid
    • ISBN: 9781498574167
    • SKU: 203436V
    • Format: VitalSource eBook/PDF


    List Price: $118.75

    Digital Product FAQs

    • Instant Access!
Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising compares the pharmaceutical advertisements placed in five popular women’s magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in White-oriented versus Black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in Black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivational value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry’s compliance with both hard and soft regulation. Neither federal recommendations nor industry guidelines resulted in the changes to DTCA envisioned by the FDA. Regulatory action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.
Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account